Biotech | October 09, 2021
Cyprium Therapeutics and Sentynl, a Zydus subsidiary announce positive data for CUTX-101, CuHis
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The company plans to submit the IND application by the end of 2021
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
The drug is also intended for the treatment of glioblastoma multiforme
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
Subscribe To Our Newsletter & Stay Updated
